# Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update
Ticker: AVIR
Company: Atea
Source: Atea
Published: 2026-03-05 21:05 EST
Original Source URL: https://ir.ateapharma.com
## Summary

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American  C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir

## Article Body
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American  C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir
## Recent Company News
- 2026-05-27 11:00 EST — [Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-presents-new-drug-drug-interaction-results-supporting-potential-best-in-class-profile-of-the-regimen-of-bemnifosbuvir-and-ruzasvir-for-the-treatment-of-hepatitis-c-virus-at-easl-congress-2026) — Source: Atea
- 2026-05-13 11:00 EST — [Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-present-three-abstracts-at-easl-2026-congress-highlighting-progress-across-viral-hepatitis-pipeline) — Source: Atea
- 2026-05-12 20:06 EST — [Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Atea
- 2026-05-05 11:00 EST — [Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-to-host-first-quarter-2026-financial-results-and-business-update-conference-call-on-may-12-2026) — Source: Atea
- 2026-03-05 21:05 EST — [Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/AVIR/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update) — Source: Atea
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)